# EvoPAR-Prostate01 (NCT06120491)

> Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

No report yet. It can be ordered.

- Drugs tested: saruparib
- Indication: metastatic castration-sensitive prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06120491
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Metastatic Castration-Sensitive Prostate Cancer
- Interventions: Saruparib; Placebo; Abiraterone Acetate; Darolutamide; Enzalutamide
- Enrollment: 1898
- Primary outcome: Radiographic Progression-Free Survival (rPFS)

## Indexed commentary on EvoPAR-Prostate01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=evopar-prostate01-nct06120491